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Abstract. Here, we report an inorganic hexagonally ordered mesoporous fibre-like carrier
made of silica as an effective drug delivery system with mineralisation potential. Fibre-like
SBA-15 has been modified by employing a simple surface activation (rehydroxylation)
procedure. The surface-rehydroxylated fibre-like SBA-15 (SBA-15-R) was used to investi-
gate the possible mechanism of hydroxyapatite (HA) nucleation and deposition onto silica’s
surface after immersion in simulated body fluid (SBF). Amorphous calcium phosphate, Ca-
deficient HA and bone-like HA deposits were observed on SBA-15-R surface consecutively
after 7, 14 and 21 days of immersion in SBF. Accordingly, our low-angle XRD, STEM and N2
adsorption/desorption results indicated that deposited ions were mostly located at the silica’s
surface and could modify the size of the mesopores. The SBA-15-R was studied in vitro as the
potential bioactive drug delivery system using doxorubicin (DOX) as a model water-soluble
and anticancer drug. The adsorbed DOX molecules were mostly located at the pore walls
and pore openings, likely together with the silanol groups. The DOX release was diffusion-
controlled and relatively slower in SBF (pH = 7.4) than in phosphate-buffered solution (pH =
5.0), most probably due to both the stronger electrostatic interactions occurring between the
DOX and the SBA-15-R and the simultaneous deposition of calcium and phosphates ions
from SBF.
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INTRODUCTION
The development of new local drug carriers for bone
diseases focuses on enhanced bioactivity—mineralisation poten-
tial, higher delivery efficiency, lower toxicity and controlled drug
release. Hexagonally ordered mesoporous silicas (HOMS), e.g.
SBA-15 or MCM-41, obtained in sol–gel process, have received
considerable attention as a drug delivery system due to their large
surface area (600–1200 m2/g), uniform mesopore size (4–10 nm),
high surface area-to-volume ratio and modifiable particle shape
(sphere to rod-like and fibre-like microparticles). The potential
role of HOMS in formulating local drug carriers for bone diseases
is emphasised in several studies (1–3). The bone bonding property
of HOMS can be demonstrated in vitro by the hydroxyapatite
layer (HA) formation on the silica’s surface in the simulated body
fluid (SBF) (4–7). A similarHA layer was also observed in vivo at
the bone/implant interface (8). The SBF solution biomimics the
blood plasma in both ionic composition and concentration and is
kept under the physiological temperature and pH (9). Impor-
tantly, the apatite layer that formed on a surface of the silica
immersed in SBF usually features low to medium crystallinity,
similar to that of the bone tissue apatite. This phenomenon has
been recently explored as a potential way of generating in situ
biomimetic HA coatings onto the implantable drug carriers (10).
The mineralisation potential of HOMS depends on their
chemical and physical properties such as pore size, specific
surface area, bulk composition and surface chemistry (6). It
has been found that high surface area of the HOMS is related
to their higher mineralisation potential. Moreover, both a
negative surface charge and porous surface of the HOMS are
important properties for the efficient nucleation, growth and
spread of the HA crystals. The mineralisation potential is
directly associated with the presence of polar silanol groups
(Si–OH) on the HOMS’ surface. It appears that the surface
silanols induce the heterogeneous nucleation of HA through
strong intermolecular bonding to the HA precursors which
are present in SBF, i.e. ions of Ca2+, PO4
3− and OH−. After
being formed and immobilised on the HOMS’ surface, the
apatite nuclei grow spontaneously into crystalline particles,
further consuming the calcium and phosphate ions from the
SBF (5,6,11). However, HOMS is synthesised/calcinated at a
temperature of 500°C or more. At these conditions, silanols
tend to condense into siloxane bridges; thus, after the thermal
treatment only, the residual hydroxyl groups are present on
the surface. This results in delayed HA formation on the
HOMS’ surface. The typical induction times for HA nucle-
ation on the surface of HOMS are in the range of 30–60 days
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(5,6,12). However, this HA formation rate is still much slower
if compared with an amorphous, hydroxyl-rich silica synthe-
sised at low temperatures. For such type of silica, the HA
deposition was reported after 7–10 days (13,14). Therefore, it
is a great challenge to design HOMS drug carriers with the
enhanced bioactivity and controlled drug release property.
In this paper, we focused on the evaluation of the HA
nucleation and deposition onto the rehydroxylated surface of the
fibre-like SBA-15 (SBA-15-R). To the best of our knowledge,
such study has not been carried out before. The mineralisation
potential of SBA-15-R was studied under biomimetic conditions.
Scanning electron microscopy (SEM) is the most common
method for morphological analysis of apatite formation on the
surface of bioactive material. However, due to SEM’s limited
resolution, the shape of a small HA nanocrystals can be only
resolved with scanning transmission electron microscope
(STEM) (15). The compositional distribution can be studied in
detail using STEM microscope combined with field emission
scanning electron microscopy mapping (FESEM). FESEM is
widely used to observe the surface and cross sections, as well as
to analyse the elemental composition by the EDX (energy
dispersive X-ray) analysis. It has been demonstrated that a
dedicated STEM microscope working in a high-angle annular
dark-fieldmode (HAADF) is capable of taking an image with an
atomic resolution (16). Therefore, the detailed insight into the
HA formation on the SBA-15-R surface was investigated by
HAADF/STEM with FESEM mapping and EDX analysis, and
also by SEM imaging, X-ray scattering and N2 adsorption/
desorption analysis. In addition, the SBA-15-R was studied
in vitro as a potential bioactive drug delivery system using
doxorubicin (DOX) as a model water-soluble and anticancer
drug, which is characterised as amphipathic weak base consisting
of an anthracycline moiety and an amino sugar (17). DOX is the
most common drug used to treat primary bone cancer (18,19). In
case of water-soluble drug such as DOX, the electrostatic
attraction between positively charged DOX and the negatively
charged SBA-15-R surface may cause the adsorption of the
solute onto the silica’s surface. The 1mgDOX load per 200mg of
SBA-15-R was designed to deliver a low dose of DOX such as
the DOX-loaded hydroxyapatite that was tested in the animal
tumour models (18). The authors found that the drug exhibited
physiological activity at very low concentrations; the IC50 value
for osteosarcoma was about 0.35 μg/mL. They also observed
minimal premature release in the extracellular region, which
could decrease the drug side effects. In this paper, we addition-
ally studied the differences in the DOX in vitro release using
release media with various pH (phosphate-buffered solution,
pH= 5.0 and SBF, pH= 7.4). In both DOX adsorption and




Pluronic P123 triblock copolymer ((EO)20(PO)70(EO)20,
Mav = 5800) tetraethyl orthosilicate (TEOS), benzylamine,
doxorubic in hydrochlor ide (DOX), ethanol and
tris(hydroxymethyl)aminomethane (TRIS) were all obtained
from Sigma-Aldrich.
Preparation of Simulated Body Fluid
SBF was prepared according to the Kokubo’s procedure (9).
To prepare 1 L of SBF, 7.996 g of NaCl, 0.350 g of NaHCO3,
0.224 g of KCl, 0.228 g of K2HPO4·3H2O, and 0.305 g of
MgCl2·6H2O were dissolved in 750 mL of deionised water. Then,
39.0 mL of hydrochloric acid (1 M) was added to the solution;
0.278 g of CaCl2, 0.071 g of Na2SO4 and 6.057 g of TRIS were
sequentially dissolved in the solution. Finally, the solution was
diluted to 1 L and adjusted to pH= 7.4 with 1Mhydrochloric acid.
Synthesis of Fibre-Like SBA-15
The synthesis of hexagonally ordered mesoporous silica,
fibre-like SBA-15, was carried out according to the modified
procedure proposed by Zhao et al. (20) using Pluronic P123
triblock copolymer as a structure-directing agent and
tetraethyl orthosilicate (TEOS) as silica source. Of Pluronic
P123, 4.0 g was dissolved in the mixture of 2 M HCl (120.0 g)
and purified water (30.0 g) at 35°C using a magnetic stirrer
(300 rpm). Then, 8.0 g of TEOS was added drop-wise, and the
reaction solution was continuously stirred to completion for
20 h. The mixture containing precipitated solid products was
aged at 80°C for 24 h without stirring and then filtrated under
reduced pressure. Solid products were washed with 100 mL of
purified water and 30 mL of absolute ethanol and dried at
40°C for 1 h in air. Finally, the products were calcinated at
500°C for 6 h in air (with heating rate of 1°C/min) in muffle
furnace (M-525, II series). The fibre-like SBA-15 material
with particle size of 10 to 20 μm was obtained by
micronisation (Fritsch, Mortar Grinder Pulverisette 2). The
micronisation lasted 20 min at 80 rpm.
Surface Activation (Rehydroxylation) of SBA-15
The calcinatedmicrometre-sized (10–20 μm) fibre-like SBA-
15 was subject to post-synthetic surface activation. During the
surface activation process, the SBA-15 is rehydroxylated in order
to increase the number of silanols (Si–OH) (21), thus to increase
the overall surface polarity (Fig. 1). Rehydroxylation of calcinated
samples was performed by immersing 1.0 g of SBA-15 in 150 mL
HCl (18 wt%), followed by stirring for 24 h (400 rpm) under
reflux. The surface-rehydroxylated SBA-15 was subsequently
placed under a vacuum for 15 min in order to remove entrapped
air bubbles. Finally, the samples were rinsed with deionised water
three times to remove any residualHCl. The pHof the last rinsing
solution was checked to confirm it was 7.0.
Fig. 1. Schematic representation of the surface activation/
rehydroxylation process of hexagonally ordered fibre-like SBA-15
leading to increased surface polarity: acid-catalysed cleavage of a
surface siloxane bridge (Si–O–Si) and subsequent generation of two
siloxanes (Si–OH)
   17 Page 2 of 13 Prokopowicz et al.          (2019) 20:17 
In order to confirm the surface activation of fibre-like
SBA-15 after the rehydroxylation procedure (which will
further be referred as SBA-15-R), the SBA-15 and SBA-15-
R samples were compared using Fourier transform infrared
spectroscopy (FTIR, Jasco model 4700), KBr tablet technique
with spectra normalisation to maximum absorption of a
dominant peak at ca. 1080 cm−1. The accessible surface
concentration of silanols in both SBA-15 and SBA-15-R
materials was calculated using semi-quantitative benzylamine
(0.015 M) adsorption method from non-polar solvent, cyclo-
hexane (22). The amount of adsorbed benzylamine on silicas’
surface at equilibrium state was determined spectrophoto-
metrically (Shimadzu, model UV-1800) at 256 nm. For both
SBA-15 and SBA-15-R materials, the benzylamine adsorp-
tion tests were repeated five times and the mean values with
standard deviations were calculated.
In Vitro Mineralisation Assay of SBA-15-R
The HA nucleation and deposition onto rehydroxylated
silica’s surface was investigated during the mineralisation
assay. For this purpose, the SBA-15-R was chosen because
the higher concentration of accessible silanols seems to
promote the HA formation on silica’s surface (23,24). Briefly,
the micrometre-sized (10–20 μm) fibre-like SBA-15-R was
dispersed in SBF at a concentration of 1 mg/mL and gently
stirred at 37°C for 7, 14 and 21 days, respectively. As
recommended by Rámila and Vallet-Regı́ (7), SBF was
exchanged after each 24 h of immersion. The samples were
then rinsed in deionised water twice and stored in a vacuum
until further characterisation.
Drug Loading
The immersion loading method was applied to the fibre-
like SBA-15-R loading experiments as previously reported
(1). In brief, the loading experiments were carried out as
follows: 200.0 mg of micrometre-sized (10–20 μm) fibre-like
SBA-15-R was added to a 5 mL doxorubicin hydrochloride
(DOX) solution 250 μg/mL in distilled deionised water
(DDI), pH close to 6.6. The mixture was stirred at room
temperature (25 ± 0.5°C) under light-sealed conditions for
24 h to reach the equilibrium state. To evaluate the DOX
loading efficacy, the supernatant was centrifuged at 16,500×g
for 10 min using a MPW-350 fixed angle rotor centrifuge
(MPW Med. Instruments, Poland). The supernatant was
collected, and the residual DOX content was determined
using the calibration curve of DOX standard solutions in DDI
by the UV-Vis measurement at 480 nm. Drug-loading
efficiency (E) was calculated using Eq. 1:
E %ð Þ ¼ actual drug loading
theoretical drug loading
 100 ð1Þ
The theoretical drug loading was based on mass fraction
of drug and SBA-15-R used to prepare samples. The same
loading procedure was performed for the non-rehydroxylated
SBA-15 as a control. For both SBA-15 and SBA-15-R, the
loading experiments were repeated five times. The results are
expressed as mean values ± standard deviations.
In Vitro Dissolution Study
Dissolution studies were performed for the micrometre-
sized (10–20 μm) fibre-like DOX-loaded SBA-15-R at different
pH values. The phosphate buffer (pH = 5.0) was used tomimic a
physiological condition at the targeted tumour site (19), and the
above-mentioned simulated body fluid (SBF, pH= 7.4) was used
for comparative purposes. The release studies were performed
on a ERWEKA USP Apparatus 4 dissolution system (closed
loop) (Erweka DFZ-720, Germany). In each experiment, the
DOX-loaded SBA-15-R samples with an approximate mass of
DOX, equal 1000 μg, were placed on glass beads in a 22.6-mm
flow-through cell. The glass beads were used to produce laminar
flow conditions and to prevent powders from descending into
the inlet tubing (25). The flow rate was 4 mL/min in attempt to
mimic in vivo conditions (26). The eluate was filtered upon
leaving the cell and was collected in fractions. At certain time
intervals, a portion of the eluate (2 mL) was taken out to
measure the released drug concentration and then fresh buffer
(2 mL) was added to keep the volume constant. Sink conditions,
where DOX concentrations in the release medium are below
10% of its aqueous solubility (2.1 mg/mL), were maintained
during the studies. The buffer solution was changed for a fresh
one every 24 h. DOX was stable in the media during the
sampling intervals. DOXwas analysed quantitatively using UV/
Vis spectroscopy at λ max = 480 nm (Shimadzu, model UV-
1800). Analytical studies were conducted in accordance with the
requirements for quantitative analyses, calibrating the detector
with a standard solution of the DOX in specific buffer. The
calibration curve was linear in the tested range from 1.0 to
40.0 μg/mL with a regression coefficient of 0.999, regardless of
buffer used. The DOX detection limit was 0.9 μg/mL. Drug
elution data were plotted as the cumulative percent of DOX
released (Q) as a function of time (t). The results were obtained
from data groups of n≥ 3 and are expressed as mean values ±
standard deviations. The same dissolution studies were per-
formed for non-rehydroxylated SBA-15 as a control.
Characterisation
The mesostructure ordering of the investigated samples
was characterised by low-angle X-ray diffraction (XRD
D/max2600, Rigaku, Japan) using the CuKα radiation. XRD
patterns were collected in the 2Θ range between 0.5° and 9°,
with a step width of 0.02° and at a scanning rate of 0.5°/min.
The crystallinity of the investigated samples was examined by
wide-angle X-ray diffraction (XRD). XRD data was recorded
on Empyrean PANalytical diffractometer using CuKα radia-
tion (40 kV and 25 mA) at a scanning rate of 4°/min with a
step width of 0.0263. The peak positions of the measured
samples were referenced to those of the JCPDS database.
The morphology of the investigated samples was
analysed using Ultrospec (FE-TEM), EDX and elemental
mapping with a JEM-2100F (JEOL) instrument operated at
200 kV. Cationic compositions were determined on selected
areas of the samples using EDX equipped with a retractable
detector with an ultrathin window. The high-angle annular
dark field (HAADF) images were obtained in a VG
HB501UX scanning TEM. Samples for TEM were sprinkled
on a carbon film with holes, supported by a copper gird.
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The parameters characterising the porosity of the
investigated samples were determined by the measure-
ments of low-temperature nitrogen adsorption–desorption
at − 196°C using a volumetric adsorption analyser ASAP
2405 (Micromeritics, Norcros, GA). Prior to the experi-
ment, all of the samples were dried overnight at 80°C
under vacuum. The specific surface areas were calculated
using the standard Brunauer–Emmett–Teller (BET) equa-
tion for nitrogen adsorption data acquired in the range of
relative pressure p/p0 in the range from 0.05 to 0.25. The
total pore volumes (Vp) were estimated from a single point
adsorption at 0.993 p/p0. The average pore diameter (Dp)
was determined from the desorption branch of the nitrogen
isotherm using the Barrett–Joyner–Halenda (BJH) proce-
dure. The unit cell parameter (a) was calculated using the




, where d100 presents the d-spacing
value of the (100) diffraction peak in XRD patterns (27).
The pore wall thickness (b) was calculated using formula
b = a −Dp where (a) represents the unit cell parameter and
Dp represents the pore diameter obtained from BJH
calculations (27).
Scanning electron microscopy (Quanta 3D FEG) at an
acceleration voltage 10–20 kV was used to show the
morphology of the investigated samples. Samples for SEM
were fixed on carbon tape and coated with Pd/Au for 2 min.
The zeta potential was used to analyse the charge
densities of SBA-15-R under the conditions of both DOX
adsorption and release studies. Zeta potential testing was
carried out using an Otasuka Electronics zeta potential
analyser (ELS-8000, Ireland). The samples were dispersed
in deionised water at concentration of 1 mg/mL, under
sonication for 5 min. The zeta potential and isoelectric
point (IEP) were measured as a function of pH by titrating
with 0.1 M HCl and 0.1 M NaOH at room temperature.
The same measurements for the SBA-15 were performed
as a control.
RESULTS
Surface Activation of SBA-15
The FTIR spectra of the starting material SBA-15 and
surface-activated SBA-15-R are shown in Fig. 2. The most
intense bands at ca. 1080 cm−1 with the shoulder at 1150 cm−1
are characteristic for (Si–O–Si) transversal optical mode and
(Si–O–Si) longitudinal optical mode asymmetric stretching
vibrations, respectively (28,29). The band at 960 cm−1
represents the Si–OH stretching vibrations of silanol groups.
Other silica network bands are located at 801 and 455 cm−1
and are signatures of (Si–O–Si) symmetric stretching
vibrations and (O–Si–O) bending vibrations, respectively.
The band at 1635 cm−1 results from (H–O–H) bending
vibrations of physisorbed molecular water. The higher
absorbance at 960 cm−1 (upwards arrow) indicates the
higher surface concentration of isolated silanols after the
rehydroxylation procedure (29). In addition, the frequency
shift of the transversal optical peak (leftwards arrow) from
1081 to 1075 cm−1 can be connected with an increase in the
Si–O bond length, resulting from hydrolysis of Si–O–Si
bridges into Si–OH groups via rehydroxylation procedure
(28). This observed frequency shift might be also related to
decrease of bridging angle based on central force network
model (28,29). The higher concentration of surface silanol
groups for SBA-15-R material was also confirmed by higher
benzylamine adsorption as compared with the non-
rehydroxylated SBA-15 material. The maximum amounts of
adsorbed benzylamine at equilibrium state were 1.52 ± 0.2
and 3.43 ± 0.7 mmol per g of silica, for SBA-15 and SBA-15-
R, respectively. The corresponding values calculated per
surface area (765 m2/g for SBA-15 and 680 m2/g for SBA-
15-R) were 2.0 ± 0.3 and 5.0 ± 1.0 μmol/m2 for SBA-15 and
SBA-15-R, respectively, showing that after rehydroxylation,
the accessible surface concentration of silanols increased by
factor of 2.5. As reported elsewhere (22,30) when employing
this rehydroxylation procedure, the concentration of surface
silanol groups should exceed 4.0 μmol/m2.
Nanostructure of SBA-15-R
Figure 3 shows a microscopic characterisation of the
SBA-15-R nanostructure side-view STEM image and corre-
sponding electron energy loss spectroscopy (EELS) mapping
with EDX profile and SEM image. Table I lists the unit cell
parameter and pore wall thickness obtained from XRD and
the N2 adsorption/desorption data of the SBA-15-R. The
microscopic analysis (Fig. 3a) indicated that the nanostructure
of the SBA-15-R consists of well-ordered nanochannels.
Based on XRD and BJH calculations (Table I), the
nanochannels were characterised by the average pore diam-
eter of 6.5 nm and pore wall thickness between nanochannels
of 4.5 nm. The EDX analysis confirmed that the material’s
surface is composed of oxygen and silicon elements. As
shown in the SEM image (Fig. 3c), the synthesised SBA-15-R
material forms fibrous, rod-like domains aggregated into
bundle-like macrostructures, the same as observed for non-
rehydroxylated SBA-15 (data not shown).
In Vitro Mineralisation of SBA-15-R
The representative STEM images of the SBA-15-R
nanostructure after 7 days of immersion in SBF are shown
in Figs. 4 (side view) and 5 (top view), along with the
corresponding EELS mapping and EDX profile. As shown in
Figs. 4 and 5, the hexagonal pore arrangement is less ordered
as compared with the parent SBA-15-R (Fig. 3a) and the
nanometre-sized clusters (bright spots in Figs. 4a and 5a) are
Fig. 2. The FTIR spectra of SBA-15 (blue line) and SBA-15-R (red
line) samples with calculated surface silanol concentration obtained
from the benzylamine adsorption studies
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present and spread throughout the entire surface. The
corresponding EDX analysis revealed that the new observed
deposit consists of calcium and phosphorous elements with a
Ca/P atomic ratio of 1.82 (Fig. 4c). This is close to the Ca/P
ratio in Ca-rich amorphous calcium phosphate (ACP; Ca/P =
1.8) (31). The EDX data has also shown other elements such
as Na and Mg, however at much lower concentration. As
shown in top-view STEM (Fig. 5), the relatively thick layer of
the Ca and P deposit was formed on the SBA-15-R surface.
These results suggest that, after immersing in SBF for 7 days,
a Ca-rich amorphous calcium phosphate (ACP) forms on the
SBA-15-R surface.
Figure 6 shows the cross-sectional view STEM image
with the corresponding EELS mapping and the EDX profile
of SBA-15-R after immersion for 14 days in the SBF. After
increasing the time of immersion in SBF to 14 days, we have
noticed additional changes in the morphology of SBA-15-R,
as shown in the cross-sectional view STEM image (Fig. 6a).
The presence of plate-shaped crystals, 10–20 nm wide and
100 nm long, in the silica network was observed. This was
accompanied by the almost uniform distribution of Ca and P
ions in the bulk of the silica network. The corresponding
EDX data (Fig. 6d) confirmed a microstructural evolution of
amorphous calcium phosphate to nanocrystalline apatite, and
the observed Ca/P atomic ratio of 1.54 was close to the value
of a Ca-deficient apatite phase (31).
Figure 7 shows the STEM image with the corresponding
EDX profile and SEM image after immersion of SBA-15-R in
SBF for 21 days. After 21 days of assay, both the STEM and
SEM images of the SBA-15-R showed accordingly the
precipitation of the biomimetic coating. The elongated fibre-
like domains of SBA-15-R have been covered with
Fig. 3. Microscopic characterisation of parent SBA-15-R. a STEM image along the nanochannels. b Enlarged STEM image of the blue square
region with corresponding EELS mapping of oxygen (O-orange) and silicon (Si-yellow). c SEM micrograph. d EDX profile
Table I. Physical Properties of SBA-15-R Before and After Immersion in SBF for 7, 14 and 21 Days: BET Surface Area (SBET), Pore Volume
(Vp), Pore Diameter (Dp), Unit Cell Parameter (a), Pore Wall Thickness (b)
SBA-15-R (days in SBF) SBET (m
2/g) Vp (cm
3/g) Dp (nm) a (nm) b (nm)
0 680 1.07 6.5 11.0 4.5
7 450 0.854 7.7 – –
14 289 0.723 10.0 – –
21 190 0.711 15.0 – –
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spherulites of around 5–10 μm, consisting of plate-like–
shaped primary crystals. The EDX measurement (Fig. 7b)
showed that in comparison to the samples immersed for
14 days in SBF, the corresponding atomic ratio of Ca/P
increased to 1.62, which is close to the Ca/P ~ 1.75 value
observed in human bone (32).
Figure 8 presents a low-angle XRD pattern of the SBA-
15-R both non-immersed and immersed in SBF for 7 and
14 days. The low-angle XRD pattern of parent SBA-15-R
confirmed the presence of (100), (110), (200) and (210) planes
indicating the highly ordered SBA-15-type 2D hexagonal
nanostructure featuring p6mm symmetry (20)—no
disorganisation of ordered pore structure was observed after
the rehydroxylation procedure. We observed that after 7 days
of immersion in SBF, the intensity of the (100) peak
decreased significantly and (110), (200) and (210) peaks
Fig. 4. The SBA-15-R after 7 days of immersion in SBF. a Side-view STEM-HAADF image along the nanochannels (bright
spots: nanoclusters of CaP precipitates). b FESEM mapping of calcium (Ca-green), phosphorous (P-red) and oxygen (O-
blue) for the enlarged image of the blue square region shown in a. c EDX profile: Ca/P = 1.82
Fig. 5. The SBA-15-R after 7 days of immersion in SBF. a Top-view STEM-HAADF image. b EELS mapping of calcium
(Ca-yellow), phosphorous (P-red) and silicon (Si-green) for the enlarged image of the blue square region shown in a
Bottom: elemental maps of Si, Ca and P
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almost vanished. Noteworthy, after 14 days in SBF, all the
characteristic low-angle XRD peaks of SBA-15-R vanished,
indicating that the hexagonal pores in the silica nanostructure
were covered by the layer of amorphous calcium phosphate
which scattering power is similar to that of silica (33).
Figure 9 shows a wide-angle XRD pattern of the SBA-
15-R immersed in SBF for various periods. After 7 days in
SBF, the presence of a broad and diffuse peak with
maxima at 25° 2Θ was observed, which appears to be a
combined amorphous phase of inorganic deposit, with Ca
and P as main components, along with silica from SBA-15-
R. After 14 days in SBF, the XRD pattern indicated the
presence of low-crystallinity hydroxyapatite-like calcium
phosphate (CaP) phase. The appearance of the HA
crystalline phase after 14 days is confirmed by the STEM
observation of rectangular plate–shaped nanocrystals (Fig.
6a). Finally, after 21 days in SBF, the wide-angle XRD
analysis confirmed that the observed spherulites with plate-
like domains (Fig. 7) are composed of hydroxyapatite
featuring crystallinity similar to that of hydroxyapatite
present in bone tissue (32).
Table I lists the N2 adsorption/desorption data of
SBA-15-R immersed in SBF for various time periods. It
can be observed that after immersion in SBF, the deposi-
tion of the Ca and P ions clearly reduced the available
pore volume and specific surface area, compared with the
parent SBA-15-R (non-immersed in SBF), most probably
due to pore blocking caused by layer of CaP precipitate at
the mesoporous structure. The comparison of the data
indicates that the mean specific surface area of SBA-15-R
after 21 days in SBF was reduced by a factor of 3.5. This
corresponds to ca. twofold increase in the mean pore
diameter, from 6.50 nm (parent SBA-15-R) to 15.0 nm
(after 21 days of immersion in SBF).
Doxorubicin Loading and In Vitro Release
Doxorubicin loading onto SBA-15 was 5.4 ± 0.09 mg/g,
whereas for SBA-15-R, it was 5.6 ± 0.14 mg/g, corresponding
to adsorption efficiency of 87 ± 7% and 90 ± 9%, respectively
(calculated using Eq. 1), under the conditions of the loading
experiment. The representative STEM images of a selected
region of DOX-loaded SBA-15-R are shown in Fig. 10a (side
view), b (top view), along with the corresponding EELS
mapping. STEM images of the DOX-loaded SBA-15-R
reveal hexagonal arrays of uniform channels (Fig. 10), which
closely resemble the SBA-15-R (Fig. 3). The corresponding
EELS data revealed that the specific organic atom (carbon
corresponding to DOX) was observed within the SBA-15-R
cross section (Fig. 10a) and on the surface (Fig. 10b). The
SBA-15-R nanochannels exhibit a gradient of the C content,
which increases from the interior (C poor) to the surface (C
rich), implying that most of drug molecules are located on the
surface, together with the silanol groups. Figure 11 shows
both the possible ionic attraction, during the loading process,
between positively charged DOX (R-NH3
+) and negatively
charged SBA-15-R surface (≡SiO−) and the co-existed
hydrogen bonds.
The drug release behaviour of both DOX-loaded SBA-
15 and SBA-15-R, as shown in Fig. 12, was studied in buffers
at pH values of 7.4 (SBF) and 5.0 (phosphate buffer) at 37°C
to mimic the different physiological conditions (19). For both
materials, the rate of the DOX release was pH-dependent
and increases with the pH decrease. The DOX release was
characterised by the biphasic release profiles with an initial
burst due to the dissolution of DOX from the outer surface
of the fibre-like microparticles followed by a subsequent
prolonged release. The highest burst release occurs at the
pH = 5.0, where almost 56 ± 2% and 46 ± 3% of the DOX
Fig. 6. The SBA-15-R after 14 days of immersion in SBF. a Cross-sectional STEM image showing rectangular plate-shaped individual
nanocrystals. For the enlarged image of the blue square region shown in a: b FESEM mapping of calcium (Ca-green) with phosphorous (P-red)
and silicon (Si-yellow) and c FESEM mapping of oxygen (O-blue) with phosphorous (P-red). d EDX profile: Ca/P = 1.54. Bottom: elemental
maps of Si, P, Ca and O
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were released within the first 24 h for SBA-15 and SBA-15-
R, respectively. At the same time, at pH = 7.4, 36 ± 1% and
32%± 3% of the DOX were released from SBA-15 and
SBA-15-R. The cumulative percent of released drug after
120 h for the SBA-15 was 98 ± 2% and 79 ± 3% (correspond-
ing to 980 ± 20 μg and 790 ± 30 μg of released DOX) at the
pH values of 5.0 and 7.4, respectively. For comparison, the
corresponding cumulative percent of released drug for SBA-
15-R was almost the same at pH = 5.0 (97 ± 3%, 970 ± 30 μg
of released DOX), but relatively lower at pH = 7.4 (72 ± 4%,
720 ± 40 μg of released DOX). For the SBA-15, the total
drug release at pH = 7.4 was found after 144 h (6 days),
whereas for SBA-15-R, it was 26 h longer and was found
after 170 h (7 days).
Fig. 7. The SBA-15-R after 21 days of immersion in SBF. a Cross-sectional STEM image: plate-
shaped nanocrystals forming spherulites. b EDX profile: Ca/P = 1.62. c, d SEM micrographs at
different magnification (arrow: plate-like domains aggregated into spherical-shaped particles made
of apatite crystals with corresponding rod-like domains aggregated into bundle-like macrostructure
of SBA-15-R)
Fig. 8. Low-angle XRD pattern of the parent SBA-15-R and immersed in SBF for various periods
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The measured zeta potential values for SBA-15 and
SBA-15-R at pHs of both DOX adsorption (pH = 6.6) and
release (pH = 5.0 or pH = 7.4) with IEP are presented in
Table II. The IEP for SBA-15 and SBA-15-R was found to
be at pH of 2.4 and 3.1, respectively. Thus, the surface of
both materials was negatively charged during the adsorp-
tion and release studies. However, the rehydroxylated
material SBA-15-R was characterised by lower values of
zeta potential at each pH compared with non-
rehydroxylated SBA-15.
DISCUSSION
This study is part of our ongoing effort to evaluate the
suitability of hexagonally ordered mesoporous silica, SBA-15,
for two biomedical applications: local anticancer drug deliv-
ery and bone tissue regeneration. In this work, we prepared
the rehydroxylated fibre-like mesoporous SBA-15 (SBA-15-
R) by a soft-template method and by employing a simple
surface activation (rehydroxylation) procedure. The SBA-15-
R was immersed in the refreshed (every 24 h) SBF to study
Fig. 9. Wide-angle XRD pattern of the SBA-15-R after 7, 14 and 21 days of immersion in SBF. Inset: reference of hydroxyapatite
Fig. 10. Microscopic characterisation of DOX-loaded SBA-15-R. a Side-view STEM-HAADF image along the nanochannels with
corresponding EELS mapping of carbon (C-red). b Top-view STEM-HAADF image with corresponding EELS mapping of carbon (C-red)
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both the mineralisation potential and the changes in the silica
nanostructure, including alteration of pore volume and size,
caused by the deposition of calcium phosphate with different
stoichiometry and particle size.
It is well known that mesoporous silica can adsorb water,
other polar solvents and ions, through creation of hydrogen
bonding between surface silanols and any neighbouring
solvent or ions (34). Thus, the extra silanol groups generated
upon rehydroxylation at the surface of SBA-15-R (cf. Figs. 1
and 2) are expected to induce stronger adsorption of ions
which are present in SBF solution. It has been recently
demonstrated that the non-modified nanostructured SBA-15
materials induced heterogeneous nucleation of the hydroxy-
apatite mineral after immersion in SBF for 30 days (5,6). Our
results may suggest that the rehydroxylation procedure could
reduce the time required for nucleation and subsequent
deposition of HA onto the SBA-15 material. We observe
that the rehydroxylated, thus more polar and silanol-reach
SBA-15-R material induces deposition of an amorphous CaP
layer after 7 days, with subsequent crystallisation into Ca-
deficient and bone-like hydroxyapatite after 14 and 21 days,
respectively. For comparison, we have reported the layer of
bone-like apatite on non-rehydroxylated SBA-15 material
after 60 days of immersion in SBF (12), whereas Vallet-Regí
and co-workers observed the similar HA layer after 30 days
(5,6). Considering the significant role of silanols in mechanism
of HA formation (23,24), their increased surface concentra-
tion seems to promote the deposition of biomimetic apatite
layer on SBA-15.
Bhattacharyya et al. (33) found that the low-angle XRD
peaks may disappear if the pores have been filled or coated
with an amorphous material which scattering power is
comparable with that of silica. Our low-angle XRD and
STEM results indicate accordingly that the ordered hexago-
nal channels cannot be clearly distinguished inside the SBA-
15-R after 7 and 14 days of immersion in SBF. This suggests
the presence of guest ions both onto the SBA-15-R surface
and pore opening, most probably by employing diffusion and
capillary adhesive forces. This is further confirmed by our N2
adsorption/desorption data (Table I), which shows that at
increasing immersion times in SBF, the pore volume de-
creases. This indicates the clogging of the SBA-15-R
mesopores by the in situ–formed CaP precipitate. This
observation is particularly relevant to drug delivery applica-
tions where drug release rates might be decelerated by the
mineral layer deposited either at the surface and/or inside
pores of the mesoporous silica.
Our results indicate that the observed nano-sized clusters
(bright spots in Figs. 4a and 5a) are amorphous in nature. As
revealed by the EDX analysis, they are mainly composed of
Ca and P elements, and having Ca/P atomic ratio of 1.82, this
precipitate can be considered as Ca-rich amorphous calcium
phosphate (Ca-rich ACP) (cf. Fig. 4c). Interestingly, we
observed a further evolution of the Ca/P ratio in the
deposited layer, along with changes in morphology and sizes
Fig. 11. The possible interaction between positively charged DOX and SBA-15-R surfaces during the loading process—illustrative visualisation
model (plan view). Atom colour: silicon (Si-gold), oxygen (O-red), hydrogen (H-white), carbon (C-grey), nitrogen (N-blue)
Fig. 12. Mean DOX release profiles (±SD, n = 3) of DOX-loaded
SBA-15 and SBA-15-R formulations at different dissolution media
(phosphate buffer solution, pH = 5.0 and SBF, pH = 7.4)
Table II. The IEP and Zeta Potential Values for SBA-15 and SBA-
15-R Samples at pH Used for DOX Adsorption (pH = 6.6) and
Release Studies (pH = 5.0 or 7.4)
Zeta potential (mV) IEP
pH = 5.0 pH = 6.6 pH = 7.4
SBA-15 − 18 − 22 − 29 2.4
SBA-15-R − 23 − 28 − 38 3.1
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of the deposited particles. After 14 days, the amorphous
precipitate turned into nanocrystalline particles with well-
defined rectangular plate-like shapes (cf. Fig. 6a), while the
Ca/P ratio decreased to 1.54 indicating the presence of Ca-
deficient hydroxyapatite. In the samples immersed in SBF for
21 days, the Ca/P ratio increased to 1.62, which is close to the
ratio of 1.67 in stoichiometric hydroxyapatite. Our XRD
results confirmed that after 21 days in SBF, the samples
indeed have contained the crystalline phase of hydroxyapatite
(cf. Fig. 9). Regarding size and shape, the particles deposited
after 21 days were predominantly spherical (spherulite-like),
composed of plate-like hydroxyapatite nanocrystals. This
spherulite-like particle morphology is commonly observed in
hydroxyapatite formed from CaP precipitate in SBF (6,13). A
relevant mechanistic description regarding the growth of
biological apatite from amorphous calcium phosphate has
been provided by Brown et al. (35). The authors proposed
that the ACP precursor subsequently transforms to calcium-
deficient hydroxyapatite by incorporating phosphate, carbon-
ate, calcium, etc. ions from the surrounding solution. There-
fore, the Ca-rich ACP observed after 7 days of immersion in
SBF may interact with the phosphate counter-ions in SBF and
subsequently form the Ca-deficient low-crystallinity apatite
with Ca/P ratio of 1.54 (1,36). As the right stoichiometry is
not achieved at this stage, the apatite crystal undergoes
further refinement resulting in the Ca/P atomic ratio of 1.62,
being now similar in composition to the bone-like apatite
(37). Considering our results, the initial stages of the
mineralisation process may be summarised in the following
steps: (1) diffusion and capillary-induced adhesion of osteo-
genic ions from the SBF into porous surface of SBA-15-R, (2)
the formation of the calcium-silicate interface as a conse-
quence of the electrostatic interactions of negatively charged
(deprotonated) surface siloxane groups (≡SiO−) with calcium
ions from SBF and (3) the formation of the amorphous
calcium phosphate layer (Ca-rich ACP) through interaction
of the calcium-terminated silica’s surface with negatively
charged phosphate ions from SBF. Feenstra and Bruyn (38)
proposed that the transformation mechanisms of ACP to
apatite at physiological pH can follow ACP dissolution; then,
a transitional octacalcium phosphate (OCP) solid-phase
reprecipitation via nucleation and growth, with a final step
involving hydrolysis of the OCP phase into the thermody-
namically more stable apatite. Therefore, it has been
proposed that ACP act as a template for the growth of the
apatite crystal.
The wide-angle XRD results (Fig. 9) confirm that the
material deposited after 21 days in SBF is semi-crystalline
hydroxyapatite. The EDX analysis (Fig. 7b) indicates that the
mineral deposit contains other elements such as Na and Mg.
These elements are typically observed in the biological
apatite of bone tissue (38) and apatite formed on implants
in SBF (39).
The effectiveness of surface-rehydroxylated fibre-like
SBA-15 (SBA-15-R) as potential bioactive drug delivery
systems was further studied in vitro using doxorubicin as a
model water-soluble anticancer drug. The topological surface
area of DOX molecule is 2.06 nm2, and the hydrodynamic
radius for DOX in water is ca. 1.5 nm (40); therefore, the
DOX molecule fits into the pores of SBA-15 materials
(41,42). This estimate was also confirmed by STEM with the
corresponding EELS (cf. Fig. 10). The details on the specific
DOX-silica interactions are reported elsewhere (43,44). It has
been already well documented that the three following types
of interactions between DOX molecules and a carrier can
exist: electrostatic, hydrogen bonding and dispersion forces.
The steric hindrance can also be a determinant of DOX
loading. The pKa of DOX is 8.0 (17); therefore, during the
sorption process at pH = 6.6, the DOX features protonated/
positively charged amino group (R-NH3
+). Based on zeta
potential measurements at pH = 6.6 (Table II), the surface of
both the SBA-15 and SBA-15-R was negatively charged (− 22
and − 28 mV, respectively), as a consequence of the
dissociation of silanol groups (≡SiOH ⇄ SiO− +H+). The
relatively lower zeta potential of SBA-15-R surface might be
explained as a consequence of the rehydroxylation procedure
in which concentration of surface accessible silanols increased
by factor 2.5 if compared with non-rehydroxylated SBA-15
(cf. Fig. 2). Thus, increased amount of dissociated silanols
caused lower charge of SBA-15-R surface. The positively
charged DOX at pH = 6.6 undergoes spontaneous deposition
onto the negatively charged SBA-15 materials’ surface and
into pores via combination of ionic attraction and hydrogen
bonding (cf. Fig. 11). The almost complete DOX loading
without significant differences in adsorption efficiency for
both materials (87 ± 7% and 90 ± 9% for SBA-15 and SBA-
15-R, respectively) might be caused by the chosen adsorption
conditions, which were well below the adsorption capacity of
used materials (data not shown). Additionally, the electro-
static attraction between silica’s surface and DOX molecules,
during the applied immersion method, promotes the drug
loading. This result is also in agreement with other reports
(45,46).
The DOX release behaviour was studied at the various
pHs to mimic the different physiological conditions (47).
Apparatus 4 dissolution was chosen as the technique for
testing this formulation because the laminar flow through the
sample cell correlates well with the likely in vivo conditions,
where a constant circulation of body fluids takes place. It is
proposed that the rate of DOX release at performed
conditions for non-rehydroxylated SBA-15 and SBA-15-R
(cf. Fig. 12) is controlled by the diffusion of molecules
through the delivery system. The drug release rate decreases
with time due to an extended distance the DOX molecules
must take to diffuse out of the deeper parts of the
nanochannels to the exterior. It is noteworthy that for other
mesoporous systems, such as MCM-41, transport via the
nanochannels is more important or even dominant (47).
In order to explain the differences in DOX release rate
for SBA-15 and SBA-15-R at different pH conditions, both
factors should be considered: the influence of surface silanols
and simultaneous deposition of calcium and phosphate ions
onto silica’s surface. It has been reported that the surface
silanols present in SBA-15 materials are characterised by pKa
ca. 2 and 8 for free (Q3, ≡SiOH) and geminal (Q2, =Si(OH)2)
silanols, respectively (22). Based on Henderson–Hasselbalch
equation (48), free silanols exist in dissociated form (≡SiO−)
at both pH values (5.0 and 7.4). In contrast, geminal silanols
stay undissociated at pH = 5.0 (=Si(OH)2) and become
partially dissociated at pH = 7.4 (=Si(OH)O−). Therefore,
the silica surface of both SBA-15 and SBA-15-R is more
negatively charged at pH = 7.4 that has been confirmed by
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zeta potential measurements (cf. Table II). DOX molecules
may interact with silanols via both ionic attraction (dissoci-
ated silanols) and hydrogen bonds (dissociated and undisso-
ciated silanols). Thus, the slower release rate of drug at pH =
7.4 for SBA-15 and SBA-15-R might be explained as a
consequence of lower zeta potentials which promoted the
electrostatic attractions (both ionic and hydrogen bonds)
between positively charged DOX and negatively charged
silica’s surface. Moreover, the SBA-15-R was characterised
by slower drug release rate compared with SBA-15, especially
at pH = 7.4 (cf. Fig. 12), most probably due to higher
concentration of surface silanols, as a consequence of the
rehydroxylation procedure (cf. Fig. 2). It might be concluded
that higher amount of accessible silanols at SBA-15-R surface
intensified the electrostatic attractions between silica surface
and DOX molecules and consequently slowed down the drug
release.
The slower DOX release rate for SBA-15 and SBA-15-R
in SBF release medium (pH = 7.4) compared with phosphate
buffer (pH = 5.0) might be also connected with simultaneous
deposition of calcium on phosphate ions onto silica’s surface
in SBF. The surface silanols not occupied by adsorbed DOX
molecules act as the nucleation centres for calcium phosphate
per se. In case of silanols occupied by adsorbed DOX, they
become accessible for calcium ions from SBF after partial
release of drug molecules. Considering that most silanols are
located in pore walls and at the pore’s entrance (49), the
forming calcium phosphate layers may clog the pores and
thus impede the release of drug molecules located inside the
pores. However, under the biomimetic conditions adapted to
drug release, the complete release of DOX was observed for
both SBA-15 and SBA-15-R. It means that the formation of
hydroxyapatite did not stop the drug diffusion but only
slowed it down.
CONCLUSIONS
Fibre-like hexagonally ordered mesoporous silica SBA-15
has been successfully modified by employing a simple surface
activation (rehydroxylation) procedure. In result, the surface
concentration of silanols (Si–OH) increased from 2 to 5 μmol/m2.
The increased surface concentration of silanols seems to enhance
the mineralisation potential characterised as the deposition of
biomimetic apatite layer onto rehydroxylated SBA-15 silica’s
surface. Our findings indicate overall that the mineralisation of
bone-like apatite on the rehydroxylated SBA-15 is a multi-stage
process, initially involving capillary-induced diffusion and adhe-
sion of ions, and interaction of calcium and phosphate ions with
the silanol groups of rehydroxylated SBA-15. The precipitation of
amorphous calcium phosphate observed initially on the surface of
rehydroxylated SBA-15 appears to be kinetically favourable in
SBF.Over time, thismetastable amorphous phase transforms into
thermodynamically more stable individual nanocrystals of hy-
droxyapatite, which subsequently form spherulite-like crystalline
aggregates with bone-like stoichiometry.
We also studied the features of rehydroxylated fibre-like
SBA-15 after immersion in doxorubicin hydrochloride solution
by using STEM images with EELS mapping. Our findings
indicate that the positively charged drug molecules are located
at the surface and inside the nanochannels. We observe that this
loading process occurs by spontaneous sorption. Our drug release
studies indicate that the rehydroxylated SBA-15 exhibits
prolonged and pH-dependent drug release profile. The drug
release is diffusion-controlled, and it decreases with time. The
concentration of surface silanols and their pH-dependent disso-
ciation cause the negative charge of silica surface and thus
influence on drug release rate. The electrostatic interactions (ionic
attraction, hydrogen bonds) between negatively charged silica’s
surface and positively charged DOX molecules might be a rate-
limiting factor influencing the drug release behaviour. The drug
releasewas slower in simulated body fluid (pH= 7.4), if compared
with phosphate buffer (pH= 5.0), mostly because of stronger
electrostatic interactions and simultaneous deposition of calcium
and phosphate ions onto the silica’s surface.
Our results demonstrate that the micrometre-sized,
rehydroxylated fibre-like SBA-15 combine the mineralisation
properties with the prolonged drug release. The obtained
results offer a promising basis for future development of
bioactive rehydroxylated mesoporous silica in the targeted
drug delivery applications.
ACKNOWLEDGMENTS
The research is a Pol i sh-Ir ish col laborat ive
project supported by the Polish National Centre for Science
(project OPUS 15 no. 2018/29/B/NZ7/00533).
Open Access This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
?
REFERENCES
1. Prokopowicz M, Czarnobaj K, Szewczyk A, Sawicki W.
Preparation and in vitro characterisation of bioactive mesopo-
rous silica microparticles for drug delivery applications. Mater
Sci Eng C. 2016;60:7–18.
2. Shadjou N, Hasanzadeh M. Silica-based mesoporous
nanobiomaterials as promoter of bone regeneration process. J
Biomed Mater Res Part A. 2015;103:3703–16.
3. Shi S, Jiang W, Zhao T, Aifantis KE, Wang H, Lin L, et al. The
application of nanomaterials in controlled drug delivery for bone
regeneration. J Biomed Mater Res Part A. 2015;103:3978–92.
4. Gomez-Vega JM, Hozumi A, Sugimura H, Takai O. Ordered
mesoporous silica coatings that induce apatite formation
in vitro. Adv Mater. 2001;13:822–5.
5. Izquierdo-Barba I, Ruiz-González L, Doadrio JC, González-
Calbet JM, Vallet-Regí M. Tissue regeneration: a new
property of mesoporous materials. Solid State Sci.
2005;7:983–9.
6. Vallet-Regí M, Ruiz-González L, Izquierdo-Barba I, González-
Calbet JM. Revisiting silica based ordered mesoporous mate-
rials: medical applications. J Mater Chem. 2006;16:26–31.
   17 Page 12 of 13 Prokopowicz et al.          (2019) 20:17 
7. Rámila A, Vallet-Regı́ M. Static and dynamic in vitro study of a
sol–gel glass bioactivity. Biomaterials. 2001;22:2301–6.
8. Díaz A, López T, Manjarrez J, Basaldella E, Martínez-Blanes
JM, Odriozola JA. Growth of hydroxyapatite in a biocompat-
ible mesoporous ordered silica. Acta Biomater. 2006;2:173–9.
9. Kokubo T, Takadama H. How useful is SBF in predicting
in vivo bone bioactivity? Biomaterials. 2006;27:2907–15.
10. Shi X, Wang Y, Wei K, Ren L, Lai C. Self-assembly of
nanohydroxyapatite in mesoporous silica. J Mater Sci Mater
Med. 2008;19:2933–40.
11. Szewczyk A, Prokopowicz M. Amino-modified mesoporous
silica SBA-15 as bifunctional drug delivery system for cefazolin:
release profile and mineralization potential. Mater Lett.
2018;227:136–40.
12. Szewczyk A, Prokopowicz M, Sawicki W, Majda D, Walker G.
Aminopropyl-functionalized mesoporous silica SBA-15 as drug
carrier for cefazolin: adsorption profiles, release studies, and
mineralization potential. Microporous Mesoporous Mater.
2019;274:113–26.
13. Prokopowicz M, Żegliński J, Gandhi A, Sawicki W, Tofail SAM.
Bioactive silica-based drug delivery systems containing doxoru-
bicin hydrochloride: in vitro studies. Colloids Surf B.
2012;93:249–59.
14. Prokopowicz M. Bioactive silica-based nanomaterials for doxo-
rubicin delivery: evaluation of structural properties associated
with release rate. Mater Sci Eng C. 2013;33:3942–50.
15. Dumelié N, Benhayoune H, Rousse-Bertrand C, Bouthors S,
Perchet A, Wortham L, et al. Characterization of electrodepos-
ited calcium phosphate coatings by complementary scanning
electron microscopy and scanning-transmission electron micros-
copy associated to X-ray microanalysis. Thin Solid Films.
2005;492:131–9.
16. Watanabe K, Yamazaki T, Hashimoto I, Shiojiri M. Atomic-
resolution annular dark-field STEM image calculations. Phys
Rev B. 2001;64:115432.
17. DrugBank. Doxorubicin hydrochloride. https://www.drugbank.ca/
salts/DBSALT000060. Accesed 20 June 2018.
18. Itokazu M, Kumazawa S, Wada E, Wenyi Y. Sustained release
of adriamycin from implanted hydroxyapatite blocks for the
treatment of experimental osteogenic sarcoma in mice. Cancer
Lett. 1996;107:11–8.
19. Fu W, Mohd Noor MH, Yusof LM, Ibrahim TAT, Keong YS,
Jaji AZ, et al. In vitro evaluation of a novel pH sensitive drug
delivery system based cockle shell-derived aragonite nanoparti-
cles against osteosarcoma. J Exp Nanosci. 2017;12:166–87.
20. Zhao D, Huo Q, Feng J, Chmelka BF, Stucky GD. Nonionic
triblock and star diblock copolymer and oligomeric surfactant
syntheses of highly ordered, hydrothermally stable, mesoporous
silica structures. J Am Chem Soc. 1998;120:6024–36.
21. Rosenholm JM, Lindén M. Wet-chemical analysis of surface
concentration of accessible groups on different amino-
functionalized mesoporous SBA-15 silicas. Chem Mater.
2007;19:5023–34.
22. Rosenholm JM, Czuryszkiewicz T, Kleitz F, Rosenholm JB,
Lindén M. On the nature of the Bronsted acidic groups on
native and functionalized mesoporous siliceous SBA-15 as
studied by benzylamine adsorption from solution. Langmuir.
2007;23:4315–23.
23. Izquierdo-Barba I, Arcos D, Sakamoto Y, Terasaki O, López-
Noriega A, Vallet-Regí M. High-performance mesoporous
bioceramics mimicking bone mineralization. Chem Mater.
2008;20:3191–8.
24. Salinas AJ, Vallet-Regí M. Bioactive ceramics: from bone grafts
to tissue engineering. RSC Adv. 2013;3:11116–31.
25. Bielen N. Performance of USP calibrator tablets in flow-through
cell apparatus. Int J Pharm. 2002;233:123–9.
26. McCarthy I. The physiology of bone blood flow: a review. J
Bone Jt Surg. 2006;88:4–9.
27. Zhang F, Yan Y, Yang H, Meng Y, Yu C, Bo Tu A, et al.
Understanding effect of wall structure on the hydrothermal
stability of mesostructured silica SBA-15. J Phys Chem B.
2005;109:8723–32.
28. Jung HY, Gupta RK, Oh EO, Kim YH, Whang CM. Vibrational
spectroscopic studies of sol–gel derived physical and chemical
bonded ORMOSILs. J Non-Cryst Solids. 2005;351:372–9.
29. Prokopowicz M. Synthesis and in vitro characterization of
freeze-dried doxorubicin-loaded silica xerogels. J Sol-Gel Sci
Technol. 2010;53:525–33.
30. Kozlova SA, Kirik SD. Post-synthetic activation of silanol
covering in the mesostructured silicate materials МСМ-41 and
SBA-15. Microporous Mesoporous Mater. 2010;133:124–33.
31. Wilson RM, Elliott JC, Dowker SEP, Rodriguez-Lorenzo LM.
Rietveld refinements and spectroscopic studies of the structure
of ca-deficient apatite. Biomaterials. 2005;26:1317–27.
32. Bonucci E. The mineralization of bone and its analogies with
other hard tissues. In: Ferreira SO, editor. Adv top Cryst
growth. InTech; 2013:145–184.
33. Bhattacharyya S, Wang H, Ducheyne P. Polymer-coated meso-
porous silica nanoparticles for the controlled release of macro-
molecules. Acta Biomater. 2012;8:3429–35.
34. Mardones LE, Legnoverde MS, Simonetti S, Basaldella EI.
Theoretical and experimental study of isothiazolinone adsorp-
tion onto ordered mesoporous silica. Appl Surf Sci.
2016;389:790–6.
35. Brown WE, Eidelman N, Tomazic B. Octacalcium phosphate as a
precursor in biomineral formation. Adv Dent Res. 1987;1:306–13.
36. Dorozhkin SV, Epple M. Biological and medical significance of
calcium phosphates. Angew Chemie Int Ed. 2002;41:3130–46.
37. Kolmas J, Krukowski S, Laskus A, Jurkitewicz M. Synthetic
hydroxyapatite in pharmaceutical applications. Ceram Int.
2016;42:2472–87.
38. Feenstra TP, De Bruyn PL. Formation of calcium phosphates in
moderately supersaturated solutions. J Phys Chem. 1979;83:475–9.
39. Li X, Chang J. Preparation of bone-like apatite–collagen
nanocomposites by a biomimetic process with phosphorylated
collagen. J Biomed Mater Res Part A. 2008;85A:293–300.
40. IUPHAR/BPS Guide To Pharmacology. Doxorubicin-ligand
page . ht tp : / /www.guidetopharmacology.org /GRAC/
LigandDisplayForward?tab=biology&ligandId=7069. Accesed
20 June 2018.
41. Pang J, Zhao L, Zhang L, Li Z, Luan Y. Folate-conjugated
hybrid SBA-15 particles for targeted anticancer drug delivery. J
Colloid Interface Sci. 2013;395:31–9.
42. Tian B, Liu S, Wu S, Lu W, Wang D, Jin L, et al. pH-responsive
poly (acrylic acid)-gated mesoporous silica and its application in
oral colon targeted drug delivery for doxorubicin. Colloids Surf
B. 2017;154:287–96.
43. Prokopowicz M, Przyjazny A. Synthesis of sol-gel mesoporous
silica materials providing a slow release of doxorubicin. J
Microencapsul. 2007;24:694–713.
44. Prokopowicz M. Atomic force microscopy technique for the
surface characterization of sol–gel derived multi-component
silica nanocomposites. Colloids Surf A Physicochem Eng Asp.
2016;504:350–7.
45. Liu X, Gao C, Shen J, Möhwald H. Multilayer microcapsules as
anti-cancer drug delivery vehicle: deposition, sustained release,
and in vitro bioactivity. Macromol Biosci. 2005;5:1209–19.
46. Gao C, Donath E, Möhwald H, Shen J. Spontaneous deposition
of water-soluble substances into microcapsules: phenomenon,
mechanism, and application. Angew Chemie Int Ed.
2002;41:3789–93.
47. Yang K-N, Zhang C-Q, Wang W, Wang PC, Zhou J-P, Liang X-
J. pH-responsive mesoporous silica nanoparticles employed in
controlled drug delivery systems for cancer treatment. Cancer
Biol Med Chinese Anti-Cancer Assoc. 2014;11:34–43.
48. Mioni R, Mioni G. A mathematical model of pH, based on the
total stoichiometric concentration of acids, bases and
ampholytes dissolved in water. Scand J Clin Lab Invest.
2015;75:452–69.
49. IdeM, El-RozM,DeCanckE, VicenteA, Planckaert T, Bogaerts T,
et al. Quantification of silanol sites for the most common mesopo-
rous ordered silicas and organosilicas: total versus accessible silanols.
Phys Chem Chem Phys. 2013;15:642–50.
   17 Page 13 of 13Fibre-Like SBA-15 as Drug Carriers for Bone Diseases          (2019) 20:17 
